Several strategies have been proposed for the prevascularization of tissue engineered constructs. However, most of them fail due to an underestimation of the complexity of the angiogenic process that requires the action of several cell types (primarily ECs and stabilizing perivascular cells) and a precise spatiotemporal deployment of growth factor gradients to reach stable and functional blood vessels or capillaries. Furthermore, even if a completely functional and stable capillary network could be achieved, the time to spontaneously anastomose with the host’s circulation after transplantation would likely be too long, compromising the functionality of the engineered tissue. The strategy proposed in CapBed will address all the shortcomings identified above. Using cells from the SVF will allow a completely extrinsic growth factor-free strategy to endothelize pre-designed networks, unlike any strategy presented before. The standalone capillary bed with a vascular axis that will be created will be able to be anastomosed with the host’s circulation following standard surgical techniques, assuring immediate perfusion. Finally, since we are starting from the capillary bed, virtually any engineered tissue, scaffold-free or not, can be combined with it, endowing it with a great clinical potential. To achieve all of this, new methods for the laser-based micropatterning of hydrogels are being developed, which will have a wide impact in the bioengineering area. At the same time, methodologies for the gentle preservation of tissues are being created having not only the capillary beds in mind but also any type of engineered tissue, which may facilitate the clinical application of tissue engineering products in general. Ultimately, CapBed will provide critical tools that can be used not only to streamline the clinical application of already created engineered tissues but also to aid in the development of other more advanced solutions for the problem of organ and tissue shortage.